Ignite Creation Date:
2025-12-24 @ 11:49 PM
Ignite Modification Date:
2026-01-11 @ 4:51 AM
Study NCT ID:
NCT04997551
Status:
UNKNOWN
Last Update Posted:
2021-08-09
First Post:
2021-08-03
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Double Blind Randomized Clinical Trial of Use of Colchicine Added to Standard Treatment in Hospitalized With Covid-19
Sponsor:
Biogipuzkoa Health Research Institute
Organization:
Study Overview
Official Title:
Double Blind Randomized Clinical Trial of Use of Colchicine Added to Standard Treatment in Hospitalized Patients With Covid-19 Infection
Status:
UNKNOWN
Status Verified Date:
2021-08
Last Known Status:
ACTIVE_NOT_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
EC CORONACOLCHI is a multicenter, double-blind and randomized clinical trial with two branches. Patients who meet all the inclusion criteria and none of the exclusion criteria will be randomized 1: 1 to be included in one of the following groups:
* Experimental group: colchicine for 2 weeks orally at the doses described, added to the standard treatment of COVID-19.
* Control group: placebo for 2 weeks orally added to standard COVID-19 treatment.
* Experimental group: colchicine for 2 weeks orally at the doses described, added to the standard treatment of COVID-19.
* Control group: placebo for 2 weeks orally added to standard COVID-19 treatment.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?: